Hikma Is Halted By US Everolimus Method-Of-Use Patent
While a Delaware district court incorrectly held Hikma’s West-Ward to a heightened standard on motivation to combine prior art, that error did not prove fatal to its decision to uphold the validity of a US patent protecting Novartis’s Afinitor everolimus treatment for RCC until May 2026.
You may also be interested in...
Patent litigation settlements have paved the way for Endo’s Par and Teva to secure the first US approvals for generic versions of Novartis’ Afinitor everolimus brand.
Germany’s off-patent industry association, Pro Generika, is finding ample support for its position that by awarding tender contracts to exclusive suppliers, health insurance funds are contributing to drug shortages in the country.
A patent-litigation settlement that Teva has reached with Ironwood and Allergan over Linzess will allow the Israeli firm to enter the US market with the linaclotide-based constipation treatment ahead of major rivals Mylan, Sandoz, Sun Pharma and Aurobindo.